Lundbeck’s potential treatment for MSA receives Fast Track Designation

The two companies have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.

EsoBiotec is a biotechnology company focusing on in vivo cell therapies that has demonstrated promising early clinical activity.

The company has received positive and constructive feedback for its lead drug product PN6047, a selective delta opioid receptor agonist, from the U.S. Food and Drug Administration (FDA).

Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.

The company has signed a letter of intent agreement with the private US biotech company, Recardio with the objective of combining both companies’ assets and forming a late clinical-stage multi-product cardiovascular-focused specialty care company.

AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.

The FDA (the United States Food and Drug Administration ) has granted ODD (orphan drug designation) to OXC-101 as a potential treatment option for patients with AML (acute myeloid leukemia).